JP2007084515A - Medicine for ameliorating anorexia of patient in low nutritional state - Google Patents
Medicine for ameliorating anorexia of patient in low nutritional state Download PDFInfo
- Publication number
- JP2007084515A JP2007084515A JP2005278445A JP2005278445A JP2007084515A JP 2007084515 A JP2007084515 A JP 2007084515A JP 2005278445 A JP2005278445 A JP 2005278445A JP 2005278445 A JP2005278445 A JP 2005278445A JP 2007084515 A JP2007084515 A JP 2007084515A
- Authority
- JP
- Japan
- Prior art keywords
- anorexia
- patient
- essential oil
- black pepper
- nutrition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000022531 anorexia Diseases 0.000 title claims abstract description 38
- 206010061428 decreased appetite Diseases 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims description 20
- 235000016709 nutrition Nutrition 0.000 title abstract description 22
- 239000000341 volatile oil Substances 0.000 claims abstract description 35
- 244000203593 Piper nigrum Species 0.000 claims abstract description 32
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 32
- 235000013614 black pepper Nutrition 0.000 claims abstract description 32
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 230000005978 brain dysfunction Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 abstract description 13
- 230000001684 chronic effect Effects 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000001052 transient effect Effects 0.000 abstract description 6
- 206010037660 Pyrexia Diseases 0.000 abstract description 5
- 208000010643 digestive system disease Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 238000003780 insertion Methods 0.000 abstract description 3
- 230000037431 insertion Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 208000004210 Pressure Ulcer Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000010340 Sleep Deprivation Diseases 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 238000002627 tracheal intubation Methods 0.000 abstract 1
- 208000002720 Malnutrition Diseases 0.000 description 33
- 235000000112 undernutrition Nutrition 0.000 description 26
- 102000007562 Serum Albumin Human genes 0.000 description 8
- 108010071390 Serum Albumin Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 230000004596 appetite loss Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000021266 loss of appetite Nutrition 0.000 description 6
- 208000019017 loss of appetite Diseases 0.000 description 6
- 235000000824 malnutrition Nutrition 0.000 description 6
- 230000001071 malnutrition Effects 0.000 description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 description 6
- 238000000222 aromatherapy Methods 0.000 description 5
- 235000019577 caloric intake Nutrition 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000003863 physical function Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 125000003447 alpha-pinene group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000000355 effect on anorexia Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- -1 terpene compounds Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、消化器系疾患などの器質的疾患や、風邪、発熱、睡眠不足、ストレスなどの一過性の症状には関連しない、重度な食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態にある患者の食欲不振改善のための薬剤に関する。 The present invention relates to chronic reductions in oral intake of nutrition due to severe anorexia, not related to organic diseases such as gastrointestinal diseases, and transient symptoms such as colds, fever, lack of sleep, and stress. It relates to a drug for improving anorexia in patients with malnutrition based on the drug.
日本人の平均寿命は、男性で７８歳、女性で８５歳に達しており、日本は世界に誇る長寿国である。それだけに今後、高齢者がいかに健康的に余生を送ることができるかは我が国にとって重要なテーマである。ヒトは「老化」という自然のプロセスによって体重や筋肉の減少、活動性や体力の低下をきたし、いわゆる「虚弱」という状態になっていくが、その結果として「寝たきり状態」になるかならないかの分かれ目は、「食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態」に至るかそうでないかによるところが大きい。
「低栄養状態」とは、栄養状態を表現する指標が一定水準以下の場合を意味し、その指標としては、Ｂｏｄｙ Ｍａｓｓ Ｉｎｄｅｘ（ＢＭＩ）を代表とする身体組成パラメータや、血清アルブミン値や血清コレステロール値などの血液データが用いられる。近年、血清アルブミン値や血清コレステロール値の低下が、余命と生活身体的機能障害の予知因子であるとされている。これらは低栄養マーカーとして機能し、前者が３．５ｇ／ｄＬ以下の場合および／または後者が１５０ｍｇ／ｄＬの場合、低栄養状態にあると判断できる。
高齢者（例えば７０歳以上）は健常成人に比較して低栄養状態になりやすい。その原因としては、認知機能障害（記憶・記銘力障害、集中力障害、遂行機能障害、判断力低下等）などの高次脳機能障害（大脳皮質部の障害）に起因して、「食事に対して口を開かない」、「食事を前にすると寝てしまう」といった慢性的な食欲不振の症状が現れやすいことが挙げられる。このような症状が現れると、自発的な摂食が困難になり、もともと体力の予備が少ないため、すぐに低栄養状態に陥る。
いったん陥った低栄養状態から脱却することは、現在の姑息的な対症療法（輸液や経管・栄養チューブ挿入による栄養補充療法）では難しく、ほとんどの人がそこから脱却できず、「寝たきり状態」になっていく。欧米の報告では、入院高齢者で蛋白質・エネルギー低栄養状態（Ｐｒｏｔｅｉｎ Ｅｎｅｒｇｙ Ｍａｌｎｕｔｒｉｔｉｏｎ：ＰＥＭ）を呈する率は２０〜５０％、ナーシング・ホーム入所者でも３０〜５０％と高率である（非特許文献１）。日本においても、入院高齢者の約３０％、平均年齢が８０〜８２歳の場合約４０％で血清アルブミン値が３．５ｇ／ｄＬ以下であるとの報告がある（非特許文献２）。さらに、在宅診療を受けている高齢者の３２〜３５％が、また、施設入所者の約４０％がＰＥＭである（非特許文献２）。
病院における外来診療の現場では、「まるっきり食べなくなった」といって家族に連れられてくる高齢者がおり、食べなくなった理由を追求すると、食欲不振が消化器系疾患など原因疾患に基づかない場合がたびたびある。このような高齢者は、入院して末梢静脈からの点滴治療を受けることで脱水状態は改善するものの、その後も食事摂取量の改善は認められず、多くの患者は、いつかは中心静脈栄養法に切り替わり、その後、経管や栄養チューブ挿入による栄養補充療法を行わざるをえなくなるといった経緯をたどる。患者はそのような治療を受けるためにベッドに臥床していることが多く、その結果、次第に筋力が衰え、ほとんどが「寝たきり状態」に移行し、誤嚥性肺炎や転倒・骨折など様々な病態を呈していく。高齢者の低栄養状態は、明らかに、疾患治癒率、合併症の程度、合併症発症率、死亡率、入院期間の延長、褥創などの老年症候群の発生といった身体的機能に悪影響を及ぼす。
以上のような事実に鑑みると、老年症候群になるまさにその入り口が「食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態」であると言える。このような高齢者の慢性的な食欲不振による低栄養状態は、身体的機能や認知機能と密接に関係しており、「寝たきり状態」を引き起こし、ひいては死に直結する問題である。これは、健常人によくある一時的な理由からくる「食事がのどを通らない」といった一過性の食欲減退とは根本的に異なる次元のものである。いったん陥った低栄養状態からの脱却が非常に難しいことは前述の通りであり、今のところ輸液や経管・栄養チューブ挿入による栄養補充療法以外にその対処方法は存在しない。従って、高齢者自らに食べる意欲を出させ、自らの口で食物を摂取し、低栄養状態から脱却させることができれば画期的なことであるが、残念ながらそのような治療方法が提案されるには至っていない。
The “undernutrition state” means a case where an index expressing the nutritional state is below a certain level, and the index includes body composition parameters such as Body Mass Index (BMI), serum albumin level and serum cholesterol. Blood data such as values are used. In recent years, a decrease in serum albumin level or serum cholesterol level is considered to be a predictor of life expectancy and physical disabilities. These function as undernutrition markers, and when the former is 3.5 g / dL or less and / or the latter is 150 mg / dL, it can be determined that they are undernutrition.
Elderly people (for example, 70 years or older) are more likely to be undernourished than healthy adults. The cause is due to higher brain dysfunction (disorders of the cerebral cortex) such as cognitive dysfunction (memory / memory impairment, concentration disorder, executive dysfunction, decline in judgment, etc.) In other words, the symptoms of chronic loss of appetite are likely to appear, such as “I do not open my mouth” and “I fall asleep before eating”. When such symptoms appear, it becomes difficult to eat voluntarily, and because of the lack of physical strength reserves, it immediately falls into a state of undernutrition.
It is difficult to get out of the undernourishment once it has fallen, with current palliative symptomatic treatment (nutritional supplementation therapy by infusion or tube / feeding tube insertion), and most people are unable to get out of it and are “bedridden” It will become. According to reports in Europe and the United States, the rate of protein energy malnutrition (PEM) in hospitalized elderly is 20-50%, and nursing home residents also have a high rate of 30-50% (non-patent literature). 1). In Japan, there is a report that about 30% of hospitalized elderly people and about 40% when the average age is 80-82 years old and the serum albumin level is 3.5 g / dL or less (Non-Patent Document 2). Furthermore, 32 to 35% of elderly people receiving home medical care and about 40% of facility residents are PEM (Non-patent Document 2).
In the outpatient clinic at the hospital, there are elderly people who are brought to their families saying `` I have completely eaten up '', and when I pursue the reason why I have stopped eating, if anorexia is not based on a causative disease such as a digestive system disease There are often. Although such elderly people are hospitalized and receive intravenous infusion treatment to improve dehydration, their dietary intake has not improved, and many patients have some time to undergo central parenteral nutrition. After that, the history of having to perform nutrition replacement therapy by inserting a tube or feeding tube is followed. Patients are often bedridden to receive such treatment, and as a result, their muscle strength gradually declines, and most of them transition to a bedridden state, and various pathological conditions such as aspiration pneumonia, falls, and fractures Presents. Undernutrition in the elderly clearly affects physical functions such as disease cure rate, degree of complications, complication rate, mortality, prolonged hospitalization, and occurrence of geriatric syndromes such as wounds.
In view of the above facts, it can be said that the very entrance to senile syndrome is “undernutrition based on chronic decrease in oral intake of nutrition due to anorexia”. Such an undernutrition state due to chronic anorexia of the elderly is closely related to physical function and cognitive function, causing a “bedridden state” and thus directly leading to death. This is a dimension that is fundamentally different from a transient loss of appetite, such as “the meal does not pass through” that comes from temporary reasons often found in healthy people. As described above, it is very difficult to get out of the malnutrition once it has fallen, and so far there is no coping method other than nutrient replacement therapy by infusion or tube / feeding tube insertion. Therefore, it is epoch-making if the elderly can motivate themselves, eat food with their own mouth, and get out of the undernutrition, but unfortunately such a treatment method is proposed It has not reached.
そこで本発明は、消化器系疾患などの器質的疾患や、風邪、発熱、睡眠不足、ストレスなどの一過性の症状には関連しない、重度な食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態にある患者、とりわけ高齢者の低栄養状態の回復を図ることを目的とした食欲不振を改善するための薬剤を提供することを目的とする。 Therefore, the present invention relates to chronic oral intake of nutrients due to severe anorexia, which is not related to organic diseases such as digestive diseases and transient symptoms such as colds, fever, lack of sleep, and stress. It is an object of the present invention to provide a drug for improving anorexia for the purpose of recovering malnutrition of a patient, particularly an elderly person, who is undernutrition based on a decrease.
本発明者らは、上記の点に鑑みて鋭意研究を進めた結果、食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態にある高齢者にブラックペッパー精油を経鼻吸入投与したところ、食欲不振が改善され、低栄養状態の回復を図ることができることを見出した。ブラックペッパー精油は、特開平４−１４９１３５号公報に食欲増進性精油として紹介されているが、ここではあくまで健常者のストレスなどによる一過性の食欲減退の改善しか対象とされておらず、低栄養状態を引き起こすほどの重度な食欲不振は対象とされていない。よって、もちろん低栄養状態を回復させるかどうかといった検討もなされていない。また、食欲増進の評価は単に被験者の自覚症状によって行われているに過ぎず、学術文献的にも科学的な裏づけがない。特開２００４−３００１０３号公報にはブラックペッパー精油が嚥下障害改善剤の有効成分となることが記載されているが、嚥下障害は食物をうまく飲み込めない状態を意味するので、食欲があるかどうかとは関係しない。従って、ブラックペッパー精油を用いることにより、重度な食欲不振による低栄養状態にある患者の食欲不振を改善し、低栄養状態の回復を図ることで、輸液や経管・栄養チューブ挿入による栄養補充療法からの脱却が可能となること、また、低栄養状態に付随する感染、褥創、転倒による骨折などの老年症候群のリスクを減らすことが可能となること、これにより介護者の負担軽減や医療費の抑制も可能となることなどを明らかにした今般の本発明者らによる研究成果は、これらの先行特許からは導き出し得ないものであると言える。 As a result of conducting extensive research in view of the above points, the present inventors have conducted nasal inhalation administration of black pepper essential oil to elderly people in an undernutrition state based on a chronic decrease in oral intake of nutrition due to anorexia. As a result, it was found that the loss of appetite was improved and the recovery of the malnutrition state could be achieved. Black pepper essential oil is introduced as an appetite-enhancing essential oil in Japanese Patent Application Laid-Open No. 4-149135, but here it is only intended for improvement of temporary loss of appetite due to stress of healthy subjects. Anorexia severe enough to cause nutritional status is not addressed. Thus, of course, no examination has been made as to whether or not to restore undernutrition. Moreover, appetite enhancement is evaluated only by the subjective symptoms of the subject, and there is no scientific support in the academic literature. Japanese Patent Application Laid-Open No. 2004-300103 describes that black pepper essential oil is an active ingredient of an agent for improving dysphagia, but dysphagia means a state in which food cannot be swallowed well. Does not matter. Therefore, the use of black pepper essential oil improves anorexia in patients who are undernourished due to severe loss of appetite and recovers from undernutrition. And the risk of geriatric syndrome such as infections, wounds, and fractures caused by falls associated with undernutrition can be reduced. It can be said that the present research results by the present inventors, which have clarified that suppression of the above, is possible, cannot be derived from these prior patents.
本発明は、このような本発明者らの研究成果に基づいてなされたものであり、本発明の食欲不振による低栄養状態にある患者の食欲不振改善のための薬剤は、請求項１記載の通り、ブラックペッパー精油を有効成分とするものである。
また、請求項２記載の薬剤は、請求項１記載の薬剤において、食欲不振が高次脳機能障害に起因するものである。
また、請求項３記載の薬剤は、請求項２記載の薬剤において、高次脳機能障害が認知機能障害である。
また、請求項４記載の薬剤は、請求項１乃至３のいずれかに記載の薬剤において、患者が７０歳以上の高齢者である。
また、請求項５記載の薬剤は、請求項１乃至４のいずれかに記載の薬剤において、有効成分が経鼻吸入形態にて適用されるブラックペッパー精油の揮発成分である。
また、本発明の食欲不振による低栄養状態にある患者の食欲不振改善のための香粧品は、請求項６記載の通り、ブラックペッパー精油を有効成分として含有してなるものである。
The present invention has been made on the basis of such research results of the present inventors, and the medicament for improving anorexia of a patient in an undernutrition state due to anorexia of the present invention is as described in
Further, in the medicine according to
Further, in the drug according to
The drug according to
The drug according to
Further, the cosmetic for improving anorexia of a patient in an undernutrition state due to anorexia according to the present invention comprises black pepper essential oil as an active ingredient as described in claim 6.
本発明によれば、消化器系疾患などの器質的疾患や、風邪、発熱、睡眠不足、ストレスなどの一過性の症状には関連しない、重度な食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態にある患者、とりわけ高齢者の低栄養状態の回復を図ることを目的とした食欲不振を改善するための薬剤を提供することができる。 According to the present invention, chronic oral intake of nutrition due to severe anorexia is not related to organic diseases such as digestive diseases, transient symptoms such as colds, fever, lack of sleep, and stress. Therefore, it is possible to provide a drug for improving anorexia for the purpose of recovering malnutrition of a patient, particularly an elderly person, who is undernutrition based on a significant decrease.
精油（エッセンシャルオイル）は、植物の木皮や果実などより発散する芳香の根源となる揮発性のテルペン化合物などの混合物であり、一般に、抗菌作用、生理作用、心理作用、生体リズム調整作用などがあることが判明している。近年、種々の植物から得られる精油の自然の芳香を利用して、人間が生まれつき持っている自然治癒力を促進しようとする療法、即ち、アロマテラピーが広く行われるようになっている。ブラックペッパー精油を用いたアロマテラピーも既に知られており、前出の特開２００４−３００１０３号公報に記載の嚥下障害改善作用もこのような適用方法によって得られるものであるが、ブラックペッパー精油を用いたアロマテラピーの効果として、重度な食欲不振による低栄養状態にある患者の食欲不振を改善し、低栄養状態の回復を図ることができることについて報告された例はない。 Essential oils (essential oils) are mixtures of volatile terpene compounds that are the source of fragrances emanating from the bark and fruits of plants, and generally have antibacterial, physiological, psychological, and biological rhythm adjustments Is known. In recent years, a therapy that promotes the natural healing power inherent in humans, that is, aromatherapy has been widely performed by utilizing the natural aroma of essential oils obtained from various plants. Aromatherapy using black pepper essential oil is already known, and the dysphagia improving action described in JP 2004-300103 A is also obtained by such an application method. As an effect of the aromatherapy used, there has been no report on an improvement in anorexia of a patient in an undernutrition state due to severe anorexia and recovery of the undernutrition state.
本発明において、ブラックペッパー精油とは、主として、ブラックペッパー（学名：Ｐｉｐｅｒ ｎｉｇｒｕｍ，科名：コショウ科）の果実から水蒸気蒸留法によって得られる、無色透明で特有の芳香を持つ揮発性油状物を意味する。その揮発成分の臭気は刺激的でスパイシーであると一般に表現される。その主成分は、α−ピネン、β−ピネン、リモネン、β−カリオフィレンなどである。 In the present invention, the black pepper essential oil mainly means a volatile oil having a unique fragrance, which is colorless and transparent, obtained by steam distillation from the fruit of black pepper (scientific name: Pipe nigrum, family name: pepper family). To do. The odor of its volatile components is generally expressed as stimulating and spicy. Its main component is α-pinene, β-pinene, limonene, β-caryophyllene and the like.
本発明のブラックペッパー精油を有効成分とする食欲不振による低栄養状態にある患者の食欲不振改善のための薬剤は、その揮発成分を患者に経鼻吸入せしめるための形態にて適用され、例えば、ブラックペッパー精油を瓶に充填したり、不織布に含浸させたりすることで製造される香粧品として実用に供せられる。このような製品は、１日１回〜数回、例えば毎食時前に、ブラックペッパー精油を含浸させた不織布を患者に嗅がせたり、食事をする部屋にブラックペッパー精油をスプレー噴霧したり、その揮発成分が揮発するようにブラックペッパー精油を充填した瓶を蓋を開けてテーブルの上に置いたりすることで用いればよい。なお、ブラックペッパー精油は、その食欲不振改善作用に悪影響を及ぼさない範囲において、エチルアルコールなどで希釈して用いてもよい。本発明の薬剤の適用対象となりうる患者としては、食欲不振による低栄養状態にある高齢者が多いが、このような高齢者に限定されるものではなく、若年性アルツハイマー病や若年女性に多い神経性食欲不振症などに起因する重度な食欲不振による低栄養状態にある成人も本発明の薬剤の適用対象となりうる。本発明の薬剤の適用期間は特段限定されるものではないが、通常、３日〜１月を目安にすればよい。 The drug for improving anorexia of a patient in an undernutrition state due to anorexia comprising the black pepper essential oil of the present invention as an active ingredient is applied in a form for inhaling the patient with the volatile component, for example, It is put to practical use as a cosmetic product produced by filling a black pepper essential oil into a bottle or impregnating a nonwoven fabric. Such a product can be used once to several times a day, for example, before a meal, by smelling a non-woven fabric impregnated with black pepper essential oil to a patient, spraying black pepper essential oil in a room to eat, The bottle filled with black pepper essential oil may be used by opening the lid and placing it on the table so that the volatile components are volatilized. The black pepper essential oil may be diluted with ethyl alcohol or the like as long as it does not adversely affect the anorexia amelioration effect. The patients to whom the drug of the present invention can be applied are many elderly people who are undernourished due to loss of appetite, but are not limited to such elderly people, and nerves common to juvenile Alzheimer's disease and young women Adults who are undernourished due to severe anorexia caused by anorexia nervosa and the like can also be applied to the drug of the present invention. Although the application period of the chemical | medical agent of this invention is not specifically limited, Usually, what is necessary is just to make 3 days-1 month into a standard.
以下、本発明を実施例によって詳細に説明するが、本発明は以下の記載によって何ら限定して解釈されるものではない。なお、以下の実施例は、ガテマラ産ブラックペッパーの果実から水蒸気蒸留法によって得た無色透明のブラックペッパー精油（山本香料株式会社（大阪）より入手）を用いて行った。 EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, this invention is not limited at all by the following description. The following examples were performed using colorless and transparent black pepper essential oil (obtained from Yamamoto Fragrance Co., Ltd. (Osaka)) obtained from a Guatemalan black pepper fruit by a steam distillation method.
症例１：８２歳の女性の脳血管障害型痴呆患者に対する効果
数ヶ月に渡り、１日当たりアルカリイオン飲料２００ｍＬと経管栄養剤６００ｍＬのみの摂取で暮らしてきたが、だんだん全身状態が悪くなり、病院に「食べない」という理由で入院した。入院時に低栄養状態（血清アルブミン値：２．７ｇ／ｄＬ、血清コレステロール値：１３２ｍｇ／ｄＬ）および脱水状態であったため、毎日、末梢静脈からの輸液の点滴１０００ｍＬとヌエットに浸したブラックペッパー精油を１日３回食事前に嗅がせて嗅覚刺激を行った。そうしたところ、治療開始当日（第１日）は食事を全く摂取せず、第２日〜第５日は食事を口にしたりしなかったりという状態であったが、第６日より食事を徐々に摂取し始め、第８日には一日の供給カロリー（１６００ｋｃａｌ）の約７割を摂取し、第１０日にてブラックペッパー精油を用いた嗅覚刺激は終了したが、第１１日には全供給カロリーを摂取し、以後約２ヶ月間に渡って食事を変わりなく全量摂取している（図１下を参照）。また、図１上に示したように、食事の摂取量に対応して、次第に栄養指標の数値も上昇した（６０日経過時点の血清アルブミン値：４．２ｇ／ｄＬ、血清コレステロール値：２０８ｍｇ／ｄＬ）。また、この患者は入院時に貧血を呈していたが（赤血球数：２３５×１０4個／μＬ、ヘモグロビン値：７．５ｇ／ｄＬ）、食事摂取とともに改善し（１５日経過時点の赤血球数：３７０×１０4個／μＬ、ヘモグロビン値：１１．２ｇ／ｄＬ）、ほぼ一定値に達した。
Case 1: Effect of a 82-year-old woman on cerebrovascular disorder-type dementia patients For several months, she has lived with only 200 mL of alkaline ion beverage and 600 mL of tube nutrient per day, but her general condition gradually worsened, and the hospital Was admitted to the hospital for the reason of not eating. Because it was undernutrition (serum albumin level: 2.7 g / dL, serum cholesterol level: 132 mg / dL) and dehydrated at the time of admission, 1000 mL of infusion from peripheral veins and black pepper essential oil soaked in Nuetto every day The olfactory stimulation was performed by sniffing 3 times a day before meals. As a result, on the first day of treatment (the first day), no food was consumed at all, and from the second day to the fifth day, no food was consumed. On the 8th day, about 70% of the daily calorie supply (1600 kcal) was ingested. On the 10th day, the olfactory stimulation using black pepper essential oil was completed, but on the 11th day, the whole supply The calorie is ingested, and after that, the whole meal is ingested for about two months without change (see the lower part of FIG. 1). In addition, as shown in FIG. 1, the numerical value of the nutritional index gradually increased corresponding to the amount of food intake (serum albumin level at the time of 60 days: 4.2 g / dL, serum cholesterol level: 208 mg / dL). In addition, although this patient had anemia at the time of hospitalization (red blood cell count: 235 × 10 4 cells / μL, hemoglobin value: 7.5 g / dL), it improved with food intake (red blood cell count after 15 days: 370). × 10 4 pieces / μL, hemoglobin value: 11.2 g / dL), reaching a substantially constant value.
症例２〜症例１２：
症例１に続き、ブラックペッパー精油が低栄養状態にある患者の食欲不振に対して改善効果を有することを確認するために、症例の蓄積を行った。
表１に示す１１名の認知機能障害に起因する重度な食欲不振による低栄養状態にある患者（ただし器質的疾患はなし）を対象に、１４日間に渡って１日３回食事前にヌエットに浸したブラックペッパー精油を嗅がせて嗅覚刺激を行った。その結果、いずれの患者も次第に食事を摂取するようになった。ブラックペッパー精油の効果について、図２にカロリー摂取量の変化、図３に血清総蛋白値の変化、図４に血清アルブミン値の変化、図５に血清コレステロール値の変化を示す。図２から明らかなように、カロリー摂取量はブラックペッパー精油を用いた嗅覚刺激により有意に改善した。１１の症例における一日必要栄養摂取量（１３７２±２８０ｋｃａｌ）の半分のカロリーがとれるまでの日数は平均５．９日であった。また、図３〜図５から明らかなように、血清総蛋白値、血清アルブミン値、血清コレステロール値といった栄養指標についても有意に改善した。以上の結果から、ブラックペッパー精油は、重度な食欲不振を改善することで、低栄養状態の回復を図るために顕著な効果があり、対象者の意識レベル、身体的日常生活レベル、認知機能レベルに関係なく、手軽でしかも効果的であることが確かめられた。
Following
11 patients in undernutrition due to severe anorexia caused by cognitive dysfunction shown in Table 1 (but without organic illness) 3 times a day for 14 days before eating The black pepper essential oil was sniffed and olfactory stimulation was performed. As a result, all patients gradually began to eat. Regarding the effect of black pepper essential oil, FIG. 2 shows changes in caloric intake, FIG. 3 shows changes in serum total protein values, FIG. 4 shows changes in serum albumin values, and FIG. 5 shows changes in serum cholesterol levels. As is clear from FIG. 2, the calorie intake was significantly improved by olfactory stimulation using black pepper essential oil. In 11 cases, the average number of days required for taking half the calorie intake per day (1372 ± 280 kcal) was 5.9 days on average. As is clear from FIGS. 3 to 5, nutritional indicators such as serum total protein level, serum albumin level, and serum cholesterol level were also significantly improved. Based on the above results, black pepper essential oil has a remarkable effect to improve undernourishment by improving severe anorexia, subject's consciousness level, physical daily life level, cognitive function level Regardless of whether or not it is easy and effective.
本発明は、消化器系疾患などの器質的疾患や、風邪、発熱、睡眠不足、ストレスなどの一過性の症状には関連しない、重度な食欲不振による栄養の経口摂取量の慢性的な低下に基づく低栄養状態にある患者、とりわけ高齢者の低栄養状態の回復を図ることを目的とした食欲不振を改善するための薬剤を提供することができる点において産業上の利用可能性を有する。 The present invention relates to chronic reductions in oral intake of nutrition due to severe anorexia, not related to organic diseases such as gastrointestinal diseases, and transient symptoms such as colds, fever, lack of sleep, and stress. The present invention has industrial applicability in that it can provide a drug for improving anorexia for the purpose of recovering malnutrition of a patient under an undernutrition based on the above, particularly the elderly.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005278445A JP4889270B2 (en) | 2005-09-26 | 2005-09-26 | Drugs for improving anorexia in patients with undernutrition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005278445A JP4889270B2 (en) | 2005-09-26 | 2005-09-26 | Drugs for improving anorexia in patients with undernutrition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007084515A true JP2007084515A (en) | 2007-04-05 |
| JP4889270B2 JP4889270B2 (en) | 2012-03-07 |
Family
ID=37971877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005278445A Expired - Fee Related JP4889270B2 (en) | 2005-09-26 | 2005-09-26 | Drugs for improving anorexia in patients with undernutrition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4889270B2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008290965A (en) * | 2007-05-24 | 2008-12-04 | Tohoku Univ | Ameliorative agent for fluctuation of body's center of gravity |
| CN104001098A (en) * | 2014-05-30 | 2014-08-27 | 马永才 | Traditional Chinese medicine for treating infant anorexia |
| CN104069458A (en) * | 2014-07-03 | 2014-10-01 | 吴晓青 | Traditional Chinese medicine composition for treating infantile anorexia |
| CN104083630A (en) * | 2014-07-04 | 2014-10-08 | 青岛大学附属医院 | Traditional Chinese medicine ointment for treating bedsore and preparation method thereof |
| CN104383485A (en) * | 2014-11-10 | 2015-03-04 | 黄结云 | Medicine for treating infantile anorexia |
| CN104873905A (en) * | 2015-06-09 | 2015-09-02 | 王慧 | Traditional Chinese medicament for treating pertussis |
| CN104873824A (en) * | 2015-06-09 | 2015-09-02 | 王慧 | Traditional Chinese medicine for treating pertussis and preparation method |
| CN105030853A (en) * | 2015-08-07 | 2015-11-11 | 成都易创思生物科技有限公司 | Method for separating and purifying kandelia candel leaf total flavonoids |
| CN105147986A (en) * | 2015-10-23 | 2015-12-16 | 戚炎月 | Weight-reducing granules |
| CN105213797A (en) * | 2015-10-27 | 2016-01-06 | 林亚梅 | A kind of Chinese medicine being used for the treatment of varicocele |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04149135A (en) * | 1990-10-09 | 1992-05-22 | Kureha Chem Ind Co Ltd | Perfume composition and perfume product therefrom |
-
2005
- 2005-09-26 JP JP2005278445A patent/JP4889270B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04149135A (en) * | 1990-10-09 | 1992-05-22 | Kureha Chem Ind Co Ltd | Perfume composition and perfume product therefrom |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008290965A (en) * | 2007-05-24 | 2008-12-04 | Tohoku Univ | Ameliorative agent for fluctuation of body's center of gravity |
| CN104001098A (en) * | 2014-05-30 | 2014-08-27 | 马永才 | Traditional Chinese medicine for treating infant anorexia |
| CN104069458A (en) * | 2014-07-03 | 2014-10-01 | 吴晓青 | Traditional Chinese medicine composition for treating infantile anorexia |
| CN104083630A (en) * | 2014-07-04 | 2014-10-08 | 青岛大学附属医院 | Traditional Chinese medicine ointment for treating bedsore and preparation method thereof |
| CN104383485A (en) * | 2014-11-10 | 2015-03-04 | 黄结云 | Medicine for treating infantile anorexia |
| CN104873905A (en) * | 2015-06-09 | 2015-09-02 | 王慧 | Traditional Chinese medicament for treating pertussis |
| CN104873824A (en) * | 2015-06-09 | 2015-09-02 | 王慧 | Traditional Chinese medicine for treating pertussis and preparation method |
| CN105030853A (en) * | 2015-08-07 | 2015-11-11 | 成都易创思生物科技有限公司 | Method for separating and purifying kandelia candel leaf total flavonoids |
| CN105147986A (en) * | 2015-10-23 | 2015-12-16 | 戚炎月 | Weight-reducing granules |
| CN105213797A (en) * | 2015-10-27 | 2016-01-06 | 林亚梅 | A kind of Chinese medicine being used for the treatment of varicocele |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4889270B2 (en) | 2012-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4889270B2 (en) | Drugs for improving anorexia in patients with undernutrition | |
| Himmerich et al. | Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences | |
| Riemann et al. | Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study | |
| JP2003334032A (en) | Health supplement food having ameliorating action for somnipathy | |
| Sharma et al. | Paraplegia as a result of lightning injury. | |
| Erkinjonovna | THE BEST WAYS TO CONTROL HIGH BLOOD PRESSURE WITHOUT MEDICATION | |
| JP7200298B2 (en) | Suppressant for diarrhea-type irritable bowel syndrome and food composition | |
| Simbar et al. | A comparative study on the effects of “honey and fenugreek” with “fenugreek” on the breastfeeding success: A randomized trial | |
| Yamagishi et al. | Sleep-improving effects of the aromatic compound heliotropin | |
| Ross | Mild to moderate depression: a complementary and integrative therapies approach | |
| KR20210097487A (en) | Composition for preventing, improving or treating sleep disorders comprising fucoidan | |
| Sarwer-Foner et al. | The clinical investigation of pacatal in open psychiatric settings | |
| Lapshin et al. | How do psychiatric patients perceive the side effects of their medications | |
| CN103960398B (en) | A kind of containing flake grass slim tea and preparation method thereof | |
| Babu | A treatise on home remedies | |
| JP2005068069A (en) | Chamomile extraction essence having bloodstream-ameliorating activity and heart rate-educing activity, and method for producing the same | |
| Smith et al. | Postmenopausal osteoporosis. | |
| CN104431057B (en) | A kind of slim tea containing desmodium triquetrum and preparation method thereof | |
| Ramaswamy et al. | Traditional Therapeutic Approach for the Management of Non-Healing, Chronic Diabetic Ulcer--A Case Report. | |
| CN107509833A (en) | A kind of slim tea containing desmodium triquetrum and preparation method thereof | |
| Datta et al. | MANAGEMENT OF GERIATRIC HEALTH ISSUES THROUGH AYURVEDA | |
| Kaplan et al. | Considerations for those providing nutritional care to the elderly | |
| JP2021153425A (en) | Composition for improving qol and adl of the elderly and suppressing deterioration of them and method for producing the same | |
| Amer Assoc of Colleges of Nurs | Ask a nurse: From home remedies to hospital care | |
| CN109662169A (en) | One kind slim tea containing desmodium triquetrum and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080603 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111031 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111031 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20111031 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20111031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111031 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111206 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111213 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4889270 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141222 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |